PMC:7054527 / 5729-5984 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"223","span":{"begin":21,"end":25},"obj":"Gene"},{"id":"224","span":{"begin":49,"end":53},"obj":"Gene"},{"id":"225","span":{"begin":217,"end":221},"obj":"Gene"},{"id":"242","span":{"begin":69,"end":77},"obj":"Species"},{"id":"243","span":{"begin":166,"end":173},"obj":"Species"},{"id":"244","span":{"begin":196,"end":205},"obj":"Species"},{"id":"249","span":{"begin":87,"end":92},"obj":"Species"},{"id":"251","span":{"begin":148,"end":165},"obj":"Disease"}],"attributes":[{"id":"A223","pred":"tao:has_database_id","subj":"223","obj":"Gene:100144303"},{"id":"A224","pred":"tao:has_database_id","subj":"224","obj":"Gene:59272"},{"id":"A225","pred":"tao:has_database_id","subj":"225","obj":"Gene:59272"},{"id":"A242","pred":"tao:has_database_id","subj":"242","obj":"Tax:694009"},{"id":"A243","pred":"tao:has_database_id","subj":"243","obj":"Tax:9606"},{"id":"A244","pred":"tao:has_database_id","subj":"244","obj":"Tax:2697049"},{"id":"A249","pred":"tao:has_database_id","subj":"249","obj":"Tax:9606"},{"id":"A251","pred":"tao:has_database_id","subj":"251","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"to the cells without ACE211,33–35. A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCo"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T30","span":{"begin":7,"end":12},"obj":"Body_part"},{"id":"T31","span":{"begin":57,"end":65},"obj":"Body_part"},{"id":"T32","span":{"begin":104,"end":112},"obj":"Body_part"},{"id":"T33","span":{"begin":122,"end":127},"obj":"Body_part"}],"attributes":[{"id":"A30","pred":"fma_id","subj":"T30","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A31","pred":"fma_id","subj":"T31","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A32","pred":"fma_id","subj":"T32","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A33","pred":"fma_id","subj":"T33","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"to the cells without ACE211,33–35. A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCo"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T12","span":{"begin":122,"end":127},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"to the cells without ACE211,33–35. A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCo"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T43","span":{"begin":69,"end":77},"obj":"Disease"},{"id":"T44","span":{"begin":69,"end":73},"obj":"Disease"},{"id":"T45","span":{"begin":148,"end":156},"obj":"Disease"},{"id":"T46","span":{"begin":148,"end":152},"obj":"Disease"}],"attributes":[{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"to the cells without ACE211,33–35. A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCo"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T49","span":{"begin":7,"end":12},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T50","span":{"begin":31,"end":33},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T51","span":{"begin":35,"end":36},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T52","span":{"begin":67,"end":68},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T53","span":{"begin":87,"end":92},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T54","span":{"begin":133,"end":134},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"to the cells without ACE211,33–35. A recombinant ACE2-Ig antibody, a SARS-CoV-specific human monoclonal antibody, and the serum from a convalescent SARS-CoV-infected patient, which can neutralize 2019-nCoV, confirmed ACE2 as the host receptor for 2019-nCo"}